Navigation Links
Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
Date:10/25/2010

EAST BRUNSWICK, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its previously announced process to identify, following the approval of KRYSTEXXA™ by the U.S. Food and Drug Administration (FDA), a strategic transaction for the sale of the Company did not result in a sale of the Company at this time. The board of directors will continue to evaluate strategic alternatives available to the Company to maximize value.

The Company is working toward the commercial launch of KRYSTEXXA, which it expects will be available by prescription in the U.S. later this year.  The Company will host a conference call on Tuesday, October 26, 2010, at 8:30 a.m. during which it will provide further detail around its launch plans.

Conference Call Information

Savient's management team will host a live conference call and webcast on October 26, 2010 at 8:30 a.m. Eastern Time. Call-in information will be provided in a separate press release shortly.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
2. Savient Pharmaceuticals To Hold First Quarter 2010 Results
3. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
5. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
6. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
7. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
9. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
11. Savient Provides Update on Pegloticase BLA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4
... Untold Numbers of Consumers Still Left Disabled By Its ... GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super ... its denture adhesive products.  The pharmaceutical giant has added the potentially ... consuming large quantities of zinc over an extended period of time ...
... , , SHANGHAI , ... WX ), a leading pharmaceutical, biotechnology and medical device R&D outsourcing ... announced that it will release financial results for the fourth quarter of ... 8, 2010 (which will be Tuesday morning, March 9, 2010 ...
Cached Medicine Technology:Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 2Leading Denture Cream Litigation Firm Welcomes GSK Announcement of Removal of Zinc From Its Denture Creams 3WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 2WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release 3
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... the wake of the 2012 Rejuvenate and ABG ... forward in New Jersey’s Bergen County Superior Court, ... in the proceeding, the Court has issued ... governing any and all hard copy and electronic ...
(Date:8/1/2014)... 2014 Summer is here, and with it ... the summer, and they can be a pain for dogs. ... help all their customers get rid of ticks and prevent ... eggs in the summer, which is why they are so ... grass and woodland areas and carry a number of diseases, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... (D-CA), Gregg Harper (R-MS), and Peter Welch (D-VT), ... the Medicare Telehealth Parity Act of 2014, which ... support this effort to improve healthcare access and ... executive officer of ATA. "These cost-saving provisions are ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... others such as Zinc Oxide, Titanium Dioxide, and ... Building & Construction, Food & Beverages, Textiles, and ... ROW) - Global Trends and Forecasts to 2018" ... market drivers, opportunities, and trends in the diverse ...
(Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... patient communities call on national policymakers in Latin America to ... people with atrial fibrillation (AF) each year, AF increases the ... five of all ischemic strokes caused by a blood clot ... of people in Latin America suffer from AF , ...
... Parker, Ph.D., assistant professor of research in the Department of ... $418,000 from the National Institute of Neurological Disorders and Stroke ... particular gene might be involved in the progression of spinal ... children younger than 2 years old. "Although most ...
... Transplantation specialists have proposed changes to the allocation and ... policy modifications take into account the scarcity of available ... to those most in need in order to reduce ... are available in the September issue of Liver ...
... Reporter , FRIDAY, Sept. 9 (HealthDay News) -- Experts ... to meet Friday to discuss problems linked to long-term ... and Reclast. These drugs, known as bisphosphonates, ... But researchers have linked long-term use with a small ...
... at the University of Maryland Medical Center have transplanted ... an experimental repair process before transplantation. The procedure is ... evaluate the efficacy of repairing, before transplant, lungs that ... organ donation. The results of this study, if successful, ...
... diagnosed each year with stage III or,locally ... not a viable,treatment option. Optimizing nonsurgical treatment ... endeavor. In an article published online,September 8, ... Cancer Institute, RTOG,researchers report that treating patients ...
Cached Medicine News:Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 2Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 3Health News:Medical and patient communities call for urgent action to prevent stroke crisis in Latin America 4Health News:Wayne State University researcher to study spinal muscular atrophy 2Health News:Changes to distribution of livers for transplant proposed 2Health News:Changes to distribution of livers for transplant proposed 3Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:First US patient receives specially processed donor lungs at the University of Maryland 2Health News:Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer 2
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With cast aluminum ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
Medicine Products: